Get the Stockscreener App
3.005
1.01%
0.045
Kyverna Therapeutics Inc stock is traded at $3.005, with a volume of 44,279.
It is up +1.01% in the last 24 hours and up +28.88% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$2.96
Open:
$2.96
24h Volume:
44,279
Relative Volume:
0.13
Market Cap:
$155.59M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-0.9705
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
-9.67%
1M Performance:
+28.88%
6M Performance:
-21.11%
1Y Performance:
-59.81%
1-Day Range:
$2.89
$3.04
1-Week Range:
$2.89
$3.575
52-Week Range:
$1.78
$11.40
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
3.00 | 155.59M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.00 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
517.83 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.28 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.29 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.58 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) PT at $18.50 - MarketBeat
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - marketscreener.com
3 Promising Penny Stocks With Market Caps Over $100M - Yahoo Finance
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Sees Large Increase in Short Interest - MarketBeat
Lead Plaintiff Appointed in Kyverna Class Action — Here’s How You Can Recover Your Losses - TradingView
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Millennium Management LLC - MarketBeat
Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 4,990 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Ameriprise Financial Inc. Raises Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts - MSN
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
BNP Paribas Financial Markets Purchases 17,786 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Northern Trust Corp Purchases 61,757 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Buy" at HC Wainwright - MarketBeat
Kyverna Therapeutics to Present at the Jefferies Global Healthca - GuruFocus
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference - PR Newswire
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Kyverna Therapeutics’ KYV-101: Promising Developments and First-to-Market Potential in Autoimmune Diseases - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to “Buy” at HC Wainwright - Defense World
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
Kyverna Therapeutics Shares Rise After Upgrade From HC Wainwright - marketscreener.com
HC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX) - Nasdaq
Kyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position - TipRanks
HC Wainwright Upgrades Kyverna Therapeutics to Buy From Neutral, Adjusts Price Target to $5 From $4 - marketscreener.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
HC Wainwright Issues Pessimistic Estimate for KYTX Earnings - MarketBeat
Analysts Offer Predictions for KYTX Q1 Earnings - MarketBeat
HC Wainwright Issues Pessimistic Outlook for KYTX Earnings - Defense World
Analysts Issue Forecasts for KYTX Q1 Earnings - Defense World
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Jacobs Levy Equity Management Inc. Buys 442,090 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Sphera Funds Management LTD. - MarketBeat
Integral Health Asset Management LLC Purchases 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Leerink Partnrs Has Positive Outlook of KYTX Q2 Earnings - Defense World
Stifel Financial Corp Buys New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Kyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPO - Bloomberg Law News
Kyverna planning to launch Phase 3 trial of KYV-101 in MG patients - Myasthenia Gravis News
With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors - Yahoo Finance
Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace - Fierce Biotech
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases - Seeking Alpha
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):